To the editor,

On December 31, 2019, novel corona virus caused pneumonia was first reported in Wuhan, China. The pathogen was soon identified as a novel corona virus from unknown origin and then was named as "corona virus of 2019" or "COVID-19". With a rapid spread of the virus, WHO declared a global pandemic on March 11, 2020. According to WHO, as of July 14, 2020, almost all countries in the world have been affected with 12,768,307 confirmed cases and 566,654 confirmed deaths due to COVID-19 (<https://covid19.who.int/>). Its highly infectious and asymptomatic transmission characteristics have made it to a pandemic in a short time \[[@CR1]\]. Vaccines are an essential countermeasure urgently needed to control the pandemic.

2-dimension and 3-dimension studies demonstrated COVID-19 virus as RNA stranded virus, surrounded by membrane (M) protein, envelope (E) protein, and the spike (S) structural protein. Genome of virus is highly packed inside nucleocapsid (N) protein which is enveloped by M, E and S protein \[[@CR2]\]. Five nonstructural proteins including ORF1ab, ORF3a, ORF7, ORF8, ORF9 and ORF10 play a critical rule in adhesion of virus to host cell and can compromise vaccine efficacy \[[@CR3]\]. SARS-CoV-2 shares genetic homology with other coronaviruses found in bats and its closest related human virus, SARS-CoV-1. The spike protein of SARS-CoV-2 has high identity with that of SARS and MERS, which might indicate the similarity of immune evasion mechanism. After publication of the full RNA genetic sequence of COVID-19 from infected patients by Chinese researchers on January 10, 2020 \[[@CR2]\], many organizations around the world started to develop vaccines, based on knowledge obtained from SARS and MERS vaccine development, by different means including inactivated whole COVID-19 virus \[[@CR4]--[@CR6]\], live attenuated virus, adenovirus-based recombinant vector RNA and DNA vaccines \[Fig. [1](#Fig1){ref-type="fig"}\]. As of August 24, 2020, WHO documented a total of 160 vaccine candidates against COVID-19, with 26 vaccines currently in clinical evaluation (Table [1](#Tab1){ref-type="table"}) and 137 under pre-clinical evaluation \[[@CR7]\]. In order to get herd immunity, an estimated 67% of population needs to be vaccinated to stop the virus spreading \[[@CR8]\]. A vaccine targeting the Spike protein receptor-binding domain (S-RBD) of SARS-CoV-2 induces protective immunity \[[@CR9]\] in phase II/III human evaluation, after safety and efficacy results in rhesus macaque \[[@CR10]\]. Meanwhile, the Ad5 vectored COVID-19 vaccine targeting the spike glycoprotein showed tolerability and immunogenicity at 28 days post-vaccination (NCT04313127) \[[@CR11]\]. A few recent studies demonstrated promising results. The Ad5-vectored COVID-19 vaccine at 5 × 10^10^ viral particles was safe, and induced significant immune responses in the majority of recipients after a single immunization (NCT04341389) \[[@CR12]\]. Analysis of 2 randomized phase 1 and phase 2 clinical trials of inactivated vaccine showed that patients had a low rate of adverse reactions and demonstrated immunogenicity (ChiCTR2000031809) \[[@CR13]\]. Phase 1/2 single-blind, randomised controlled trial with adenovirus vaccine that expresses the spike protein of SARS-CoV-2 in chimpanzee (ChAdOx1 nCoV-19) showed an acceptable safety profile, and homologous boosting increased antibody responses \[[@CR14]\]. Meanwhile clinical trial of mRNA-1273 vaccine results showed vaccination of nonhuman primates induced robust SARS-CoV-2 neutralizing activity, rapid protection in the upper and lower airways, and no pathologic changes in the lung \[[@CR15], [@CR16]\]. Another mRNA-based vaccine BNT162 was initiated phase I/II trial in China (ChiCTR2000034825).Fig. 1Distribution of COVID-19 vaccine types under development.Data modified from the WHO website: <https://www.who.int/blueprint/priority-diseases/key-action/novel-coronavirus-landscape-ncov.pdf>Table 126 candidate vaccines in clinical evaluationPlatformType of candidate vaccineDeveloperCoronavirus targetCurrent stage of clinical evaluation/regulatory status coronavirus candidateEstimated enrollmentSame platform for non-Coronavirus candidatesTrial start dateEstimated completion dateDNADNA plasmid vaccine with electroporationInovio PharmaceuticalsINO-4800, Spike glycoprotein of SARS-CoV-2Phase 1/2NCT04447781NCT04336410160120multiple candidatesJune 22, 2020April 3, 2020February 22, 2022July 2021DNADNA plasmid vaccine + AdjuvantOsaka University/ AnGes/ Takara BioDNA vaccine (AG0301-COVID19)Phase 1/2 NCT0446347230June 29, 2020July 31, 2021DNADNA plasmid vaccineCadila Healthcare LimitedDNA COVID-19Phase 1/2 CTRI/2020/07/0263521048July 1, 2020N/ADNADNA Vaccine (GX-19)Genexine ConsortiumDNA COVID-19Phase 1 NCT04445389210June 17, 2020June 17, 2022InactivatedInactivated + alumSinovacInactivated COVID-19 virusPhase 3 NCT04456595Phase 1/2NCT04383574NCT043526088870422744SARSJuly 2020May 20, 2020April 16, 2020October 2021July 20, 2020December 13, 2020InactivatedInactivatedWuhan institute of Biological Products/SinopharmInactivated COVID-19 virusPhase 1/2 ChiCTR20000318091456April 11, 2020November 10, 2021InactivatedInactivatedBeijing Institute of Biological Products/SinopharmInactivated COVID-19 virusPhase 1/2 ChiCTR20000324591456April 28, 2020November 28, 2021InactivatedWhole-Virion InactivatedBharat BiotechInactivated COVID-19 virusPhase 1/2 CTRI/2020/07/0263001125InactivatedInactivatedInstitute of Medical Biology, Chinese Academy of Medical SciencesInactivated COVID-19Phase 1 NCT04412538942May 15, 2020September, 2021NonReplicating Viral VectorChAdOx1University of Oxford/AstraZeneca/Serum Institute of IndiaRecombinant COVID-19 (chimpanzee adenovirus vector ChAdOx1)Phase 3 ISRCTN89951424Phase2b/3 EUCTR2020-001228--32-GBPhase 1/2 PACTR2020069221200012,3302000MERS, influenza, TB, Chikungunya, Zika, MenB, plagueMay 01, 2020 June 24, 2020July 31, 2021 December 30, 2021NonReplicating Viral VectorAdenovirus Type 5 VectorCanSino Biological Inc./Beijing Institute of BiotechnologyRecombinant COVID-19 (Adenovirus Vector)Phase 2 ChiCTR2000031781Phase 1 ChiCTR2000030906500108EbolaApril 12, 2020March 16, 2020January 31, 2021December 31, 2020NonReplicating Viral VectorAdeno-basedGamaleya Research InstituteRecombinant COVID-19 adenovirus vectorPhase 1NCT04436471NCT044378753838June 17, 2020August 15, 2020ProteinRecombinant Novel Coronavirus Vaccine (Adenovirus Vector)Hubei Provincial CDCRecombinant COVID-19 (Adenovirus Vector)Phase II NCT04341389508April 12, 2020January 31, 2021ProteinAdenovirus Type 5 VectorHubei Provincial CDCRecombinant COVID-19 (Adenovirus Type 5 Vector)Phase I NCT04313127108March 15, 2020December 30, 2020Protein SubunitFull length recombinant SARs CoV-2 glycoprotein nanoparticle vaccine adjuvanted with Matrix MNovavaxSARS-CoV-2 rS (COVID-19) nanoparticlePhase 1/2 NCT04368988131RSV; CCHF, HPV, VZV, EBOVMay 25, 2020July 31, 2021Protein SubunitNative like Trimeric subunit Spike Protein vaccineClover Biopharmaceuticals Inc./GSK/DynavaxRecombinant SARS-CoV-2 trimeric s protein subunit vaccine for COVID-19Phase 1 NCT04405908150HIV, REV InfluenzaJune 19, 2020March 30, 2021Protein SubunitAdjuvanted recombinant protein (RBDDimer)Anhui Zhifei Longcom Biopharmaceutical/ Institute of Microbiology, Chinese Academy of SciencesAdjuvanted recombinant protein (RBDDimer) (CHO Cells)Phase 1 NCT0444519450MERSJune 22, 2020September 20, 2021Protein SubunitRecombinant spike protein with Advax™ adjuvantVaxine Pty Ltd/MedytoxRecombinant spike proteinPhase 1 NCT0445385240June 30, 2020July 1, 2021Protein SubunitMolecular clamp stabilized Spike proteinUniversity of Queensland/GSK/DynavaxMolecular clamp stabilized Spike proteinPhase 1 ACTRN12620000674932p120Nipah, influenza, Ebola, LassaRNALNP-encapsulated mRNAModerna NIAIDmRNA-1273 COVID-19Phase 2 NCT04405076Phase 1 NCT04283461600120multiple candidatesMay 29, 2020 March 16, 2020August, 2021November 22, 2021RNA3 LNP-mRNAsbiotech/Fosum Pharma/PfizerRNA COVID-19Phase ½ EUCTR2020-001038--36-DE NCT0436872844432,000April 20, 2020April 29, 2020January 23, 2023RNALNP-nCoVsaRNAImperial College LondonLNP-nCoVsaRNAPhase 1 ISRCTN17072692320EBOV; LASV, MARV, Inf (H7N9), RABVApril, 2020July, 2021RNAmRNACurevacmRNA Vaccine CVnCoVPhase 1 NCT04449276168RABV, LASV, YFV; MERS, InfA, ZIKV, DENV, NIPVJune 18, 2020August, 2021RNAmRNAPeople\'s Liberation Army (PLA) Academy of Military Sciences/Walvax BiotechmRNA COVID-19Phase 1 ChiCTR2000034112168June 25, 2020December 31, 2021RNAmRNAJiangsu Provincial CDCSARS-CoV-2 mRNA vaccine (BNT162b1)Phase I ChiCTR2000034825144July 20, 2020December 31, 2020VLPPlant-derived VLP adjuvanted with GSK or Dynavax adjsMedicago IncCoronavirus-like particle COVID-19Phase 1 NCT04450004180Flu, Rotavirus, Norovirus, West Nile virus, CancerJuly 10, 2020April 30, 2021Data modified from the WHO website: <https://www.who.int/blueprint/priority-diseases/key-action/novel-coronavirus-landscape-ncov.pdf>

Both live-attenuated vaccines and inactivated vaccines are highly established in product development and manufacturing process but require handling live virus. Meanwhile recombinant protein-based and vector-based vaccines are safe but require epitope selection, antigen design, and vehicle development. Some new-generation vaccine types were not produced on large scale before. RNA and DNA vaccines are two new vaccine technologies currently in focus for COVID-19 vaccine development.

Vaccine development for COVID-19 is a highly complex process involving viral genomic studies, identification of target for vaccine, vaccine design, manufacturing, storage and distribution, preclinical and clinical safety and efficacy studies. The high levels of efforts and global collaboration at this scale is unprecedented. Due to the special nature of this novel virus, vaccine development for COVID-19 seems to be very challenging. However, with the accumulation of more knowledge about the virus and the efforts of global scientific cooperation, the covid-19 vaccine will be successfully developed, and the COVID-19 pandemic will eventually be controlled.
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